to be, over the phone, I think I gave it, pretty all embracing title and I found myself lumbered with that after a few days and I thought well what am I going to do about this. So, I just divided this into three areas. The first two, the first is how osteoblast/stromal cells communicate with hemopoietic cells predominantly for osteoclast formation and activity and that takes me back to work and 00:04:41.0 considerations that I had more than 20 years ago with Gideon. And the second, and I'll just summarize that fairly briefly because this field and the people here really know quite a lot about that. The second is another aspect of communication that is how cells of the immune system communicate between themselves and with bone cells and that's an emerging field. It's actually one that has come out 00:05:09.0 of the Avioli stable and continues to come with excellent work out of the Avioli graduates, if you like particularly Roberto Pacifici and I'm going to make that a very short summary also and just take an example or two. And finally, I'm going to spend most of the time on something that we know a little less about that that is the coupling of bone formation to resorption. I'm going to draw on several lines of 00:05:38.0 evidence to make an argument that maybe the osteoclasts themselves make at least something that contributes to this formation. Now this slide is 25 years old and I just use it to illustrate the sort of thinking that led us to suggest that cells that resorbing hormones needed to act first on cells of the osteoblasts lineage in order to promote osteoclast formation and activity and this observation was 00:06:10.0 that in osteoblast rich calvarial cells and in osteogenic sarcoma cells. This was before the osteogenic sarcoma was cloned. The osteoblast-like osteogenic sarcoma cells that, in this case, prostaglandin E and a number of metabolites and analogs that were able to head certain potencies in stimulating cylokine formation in this rapid assay of just a few minutes and this relative potency that they 00:06:36.0 exerted on the osteoblastic cells very closely resembled the relative potencies that they exerted in promoting bone resorption in organ culture, a very different assay of about 48 hours at least organ culture finishing up with an increase in the number and activity of osteoclasts. And it was that sort of observation with prostaglandins and with various peptide lengths of PTH that led Gideon and 00:07:04.0 myself to think that why together with the observation in the late 1970s of Alen Boyd in using electromicroscopy that PTH treatment of bone resulted in a rapid contraction of lining cells, perhaps raising the possibility that this might expose the bone surface to the osteoclasts above it. So that in the early '80s, thoughts were summarized on this slide that was drawn 23 years ago and its pretty 00:07:36.0 crude, but the concept was that these resolving factors that we knew were capable of resorption at that time acted on osteoblastic cells and then did things that we did not understand at all, but that we said might comprise chemotaxis, maturation, and activation to cells of the osteoclasts of the hemopoietic lineage resulting in active osteoclasts. We knew or strongly suspected at that time that 00:08:00.0 calcitonin was acting directly on the osteoclast, whereas these others were not. Well that was the view, which was quite independently arrived at by Tim Chambers in London, who reasoned, not unreasonably, that osteoclasts were wandering cells, they went changing on bone cells and it made sense for them to have the formation and activity programmed by cells of a genuine bone cells, cells of the 00:08:31.0 osteoblast lineage. In fact, Chambers more than anybody else spent the next few years compiling evidence to support this hypothesis. I am not going to show any data slides here, but just to make the point that when he developed the method of culturing freshly isolated osteoclasts from lung bones of the rats or mice, and showed that the activity of those osteoclast reabsorption on bone slices 00:09:00.0 required the participation of cells other than the osteoclasts themselves. In other words, that in fact the compiling evidence that reproduced was the cells of the osteoblast lineage were required and that a factor or factors were produced by the osteoblast lineage, which controlled at least osteoclast activity. Others contributed during that time and we did and many others, but I stress the tremendous 00:09:35.0 contribution that the Chambers left back. Then by the second half of the 1980s, further developments took place led by the work of Takahashi first when he was able to form osteoclasts in a marrow culture and show that it would stimulate these when there was appropriate content of marrow stromal cells. Stimulate this with vitamin D or active vitamin D or parathyroid hormone and that work was begun 00:10:07.0 when he was working with David Roodman and Greg Mundy, but then when he returned to Japan to Showa University with Tatsuo Suda. He made a further very major contribution and that is to develop the coculture system for studying osteoclast formation that has made such a tremendous contribution. Since that time and still and that is summarized on this cartoon of mouse, in which the mass calvarial 00:10:35.0 osteoblastic cells or any of a number of stromal osteoplastic cells, but co-cultured with hemopoietic cells it is spleen or marrow and treated with, in this case vitamin D. But the same result with any of the resultant stimulators and what was found was that these cells needed to be grown together and on the same surface in order for osteoclast to be formed. In other words, it was consistent with 00:11:02.0 a contact dependent process that was necessary for these osteoblastics cells to program osteoclast formation. So that enabled us by the early 1990s to summarize the situation in this way that three groups of active agents vitamin D through which the stromal receptor the hormones and prostlaglandins that act through cAMP. The gp 130 transmits to the gp 130 cytokines. Three quite different initial 00:11:39.0 signaling mechanisms all finish up with the same effect on the osteoblastic stromal cell of conferring on the ability true by contact dependent mechanism promote osteoclast formation from hemopoietic precursors. The concept there was shown in the red, undefined at that stage osteoclast differentiation factor or ODF as reported with the Suda group and what Tim Chambers call stromal osteoblast 00:12:13.0 forming activity, or SOFA. The rest is history as they say, I am not going into any detail, but those methods were absolutely crucial in the final stages of the discovery of OPG RANKL system. The OPG was discovered independently by the Snow Brand group in Japan and the Amgen group in US and each of them knew when they discovered OPG and it is action that it was hardly likely that this separated member of the chain F receptor family could play a central role in this process of osteoclast formation. On that basis and again using the methods of Takahashi et al, they were able to isolate interval clone RANKL and identify the receptor rank with which it interacted, and of course, OPG is a decoy receptor and is a crucial regulator of this. So, I just finally with regard to this system of communication, just a 00:13:20.0 little bit more detail on this slide showing that the RANKL system is not only involved and required for osteoclast formation, but also for survival and activity of the osteoclasts and OPG, of course, is a very powerful parachrome regulator of the system. Now all of this has been, and I am not going to show any detail at all, all of these the importance of this system, physiologically, is absolutely 00:13:54.0 established by the genetic experiments of over expressions and nullification of the proteins that have been carried out by predominately by the Amgen group, but also by the Japanese group. So, we can have no doubt of the dominant role in physiology of the RANKL/RANK system and its regulation by OPG. Now what about the immune system over the last several years this is certainly something that Lou Avioli was 00:14:20.0 personally was interested in, I know. We know that T and B cells produce various cytokines that can influence osteoclast formation. Predominantly inhibitors, but certainly some obvious and classic stimulators of osteoclast formational activity including particularly RANKL and TNF alpha. IL-12 and IL-13 and IL-10 or anti-inflammatory. But the speculation has been with many of the in vitro studies on these cytokines produced by cells of the immune system or maybe they contribute in some way to the regulation of resorption and association with inflammatory bone disease. For example, periodontal disease or rheumatoid arthritis. 00:15:43.0 What about in physiology? We do not have any doubt about the supremacy of the RANKL system, but I will just give you an example using the IL-18 and IL-12, these prove inflammatory cytokines. Just briefly summarizing the inactions of IL-18 Matthew Gillespie's lab discovered, Nicky (inaudible), as a powerful inhibitor of osteoclast formation, which does so by acting first on the T-cell to generate GM-CSF, which then 00:16:15.0 is the inhibitor that mediates the IL-18 action. They found out also that IL-12 powerfully inhibits osteoclast formation by a T-cell dependent mechanism and through the generation of an inhibitory mediator, the nature of, which we do not know. It is none of the known T-cell derived mediators of inhibitors of osteoclast activity, so an unknown mediator with IL-12. The other interesting thing that IL-18 and 00:16:46.0 IL-12 together, just as in their effects on immune function, each potentiates very greatly the sensitivity of response to the other. Now in looking at these knockout mice, Natalie Sims has found that there is indeed a bone phenotype that is readily recognizable with each of these of these knockouts. I will just show one slide of Natalie's work with IL-12 and IL-18 knockout mice with 00:17:15.0 significantly decreased trabecular bone volume and in a case of IL-18, decreased trabecular number. The double knockout has about the same effects on bone volume and number, but a notably greater trabecular separation. Now, I show this only to make the point that the fact that there is a phenotype that is recognizable when these cytokines are knocked out indicates to us that possibly there may 00:17:45.0 be some physiological contribution and it was interesting to hear the presentation of Francisco from (inaudible) about a day or two ago, in which they have focussed upon how T-cells at sites of osteoclast activity can be very closely associated with osteoclasts near the endosteal surface and that maybe that such geographic proximity is necessary and maybe that process would be a crucial 00:18:15.0 part of any physiological contribution that these such cytokines made. We're still left, though, with the fact that they're produced in large amounts in inflammatory bone disease and maybe that is their major role. Now, I am going to move now to the reminder of the token talk about the coupling of bone formation to resorption. I am going to use evidence from quite an apparently disparate number of lines, but 00:18:47.0 I have to bring it together. Now, what do we mean by the coupling of the bone formation to resorption. We mean that process, in which resorption is undertaken by osteoclasts and that resorbed bone, after the osteoclasts die and/or move away, the resorbed bone is replaced by an amount that ideally we would say is equal to the amount that has been lost and that is often what is taught. But I might 00:19:14.0 just come back to that at the end. What are the mechanisms of this process that take place in BM use throughout the skeleton. I am going to spend a moment or two first on how growth factors might be involved in this in the communication process. And one of the favored views of important factors in this mechanism is that growth factors of the matrix are released during resorption and contribute to the 00:19:49.0 formation or the differentiation and activity of the osteoblasts. For example, the IGFs with the Baylink's group suggesting this many years ago that IGF-I and IGF-II might be involved in the coupling of bone formation to resorption. The IGFs being stored in abundance in the matrix and requiring activation. And (inaudible) Bikle and his laboratory a couple of years ago showed that the anabolic effect of 00:20:17.0 PTH is considerably reduced in the IGF-I knockout animals again, supporting this possibility. TGFbeta is another one that in fact Mike Centrellaet, Erine Canalis, and colleagues, have suggested is maybe important too. And, of course, TGFbeta is in abundance in the skeleton and needs to be activated, could be activated by acid as the Mundy laboratory has suggested and we have suggested that the plasminogen activator system might 00:20:49.0 activate it and the plasminogen activated system has also been shown to free IGF-I from inactivating binding proteins. So there are proteases and acidification mechanisms that could be responsible for activation. My thoughts about this over the years have been that it would be a difficult thing to rely upon getting quantitative control to rely on resorption of perhaps heterogeneously distributed 00:21:18.0 growth factors to rely too much on this being accurately supplied to replace bone formation. There is another way that this could be so, and I am going to use an evidence from Alan Boyde here and a few slides that Alan very kindly gave me and it is a topic that I have talked and enjoyed in talking with him about for quite sometime. What Alan Boyde did, what his laboratory did, Sheela Jones and Alan 00:21:48.0 Boyde, was to resorb pits on dentine, in this case, and played out calvarial osteoblastic cells on those resorbed dentine slices. And what they found was that the only areas in which Lysine red positive and bone like material was made, was in the pits and there was nothing made in other places. They took it further and their machine made grooves in these bones and again played out these osteoblastic 00:22:20.0 cells and the only places that they adhered tightly and started to differentiate where in those grooves and this shows a view of the grooves. This shows one on EM and early stage of the culture and in section on this one and the feature of this is that these cells attach very strongly and they make this Lysine red positive material really virtually up to the level that's required to fill that 00:22:48.0 space. Finally, and really quite extraordinarily, he is even plated these slices with gold and the same thing happens. So, it is the space that the cells recognize, they're able to sense the spacial requirements, and so, they could only really be doing that by communicating with each other and the most likely way of communicating is by growth factors or cytokines if they produce and worked upon each other 00:23:15.0 in a paracrine and autocrine way. So, it is possible that this is another way. It is not exclusive of the resorption of growth factors from matrix, but it is another way, in which the growth factors could be involved in this process and it is entirely consistent with the results of Bickle and others have got from the use of growth factor knockout mice. Now, finally, I have 00:23:41.0 talked about how the osteoblasts might communicate among each other, what about how could osteoclasts contribute directly to this coupling process. The remainder of time is what I am going to try and argue to you using again number of lines of evidence. First of all, I will just take these three papers and the third of which is from Natalie Sims and JCI early this year, which I will go into in 00:24:12.0 little more detail, but make a point about this paper of Victor Ring's Laboratory in which, they had developed a TGFbeta transgenic mass directed to the osteoblast, which had greatly increased bone turn over, an increased formation and resorption with a net loss of bone. And I will just summarize on this slide one feature of the work that I wanted to show. The actual data of mineral apposition 00:24:40.0 rate is bone formation is in the inset and it is graphed in another way here. D4 is the transgenic mouse with TGFbeta expressed in the mature osteoblast showing the increased mineral apposition rate increased bone formation. E1 is a transgenic mouse in which the TGFbeta receptor in the mature osteoblast was rendered null, inactive TGFbeta receptor. What the important thing was that when the 00:25:11.0 TGFbeta transgenics were crossed with the TGFbeta receptor null mice, the increased bone formation was retained and the conclusion from that series of experiments and others in that paper was that it was that some aspect of the resorption itself that was contributing to the formation response and not the TGFbeta. Now this data here is from the lab of Nobi Udagawa and Nao Takahashi, Nakamura et al and 00:25:46.0 this allows us to start to progress towards the role of the osteoclast. These are studies in the OPG knockout mice that they had access to, which, of course, have very low amount of bone. They have a great increase in bone resorption and osteoclast formation and activity because they lack completely the physiological paracrine function of OPG. If we look on the right hand side, these OPG knockout 00:26:22.0 mice have been treated with either control or with bisphosphonates to inhibit resorption. So controls on the left in each of these slides controls and bisphosphonates, OPG knockout and bisphosphonates. In each case, the bisphosphonates, of course, was successful in blocking resorption, but it also greatly inhibited formation whether it be mineral apposition rate, osteoblast surface, bone formation 00:26:50.0 rate, so that all the osteoblast and formation parameters were decreased. It was the view of the authors that this was more likely to be an activity of cell-based origin rather than matrix and part of the reasoning for that was that they noted consistently in histology in these bones that the active-looking plump cuboidal synthesizing osteoclasts were closely associated with active resorption sites. 00:27:28.0 So there is a suggestion from that there may be a cell-based origin. Now, I am going to a spend a few minutes on this data of Natalie Sims, in which we were able to work with mice that had the gp130 signaling pathways selectively inactivated and these were mice that were prepared in the laboratory of the Matthias Ernst. Matthias Ernst incidentally has worked in cancer research now and was a 00:27:56.0 former fellow of Gideon Rodan's. Matthias' lab and Brendan Jenkin's produced mice in which they selectively activated either the stat 13 signaling through the gp130 uses or the SHP2/ RAS/MAP Kinase. The stat 13 mice were generated by a deletion of that whole region. The SHP 2/RAS/MAP Kinase inactivation was achieved by a single amino acid change from tyrosine to phenylalanine at residue 757, so two 00:28:34.0 types of mice and the one that we are going to be concentrating on most is the SHP2/RAS/MAPK inactivated that is why 757F or as will be in some slots, the FF mice. The relevant features of these phenotypes were that in the SHP2/RAS/MAPK kinase, the 757 F mice there is clearly decreased trabecular bone volume number and trabecular thickness. I am not saying anything more about the delta stat mice. 00:29:08.0 They had no changes on dynamic histomorphometry. The predominant feature was a shortening of long bones, which was related to a chondrocyte phenotype. So we are not going to consider the delta stat mice any further. The important thing here is the decreased bone mass of the FF mice. This is because of increases both in resorption and formation with a net loss. This shows resorption data with 00:29:36.0 increased osteoclast surface both in males and in females and the histology there showing the active osteoplast. Now that osteoclast formation from the bone marrow cells is elevated in this work of Julian Quinn's. We wanted to be sure that this was indeed a cell autonomous effect, and so, he did the same thing in bone marrow macrophages prepared from these marrows and this same increased osteoclast formation was 00:30:10.0 formed. So that was evidenced. So in other words, there is a cell autonomous increase in osteoclast formation, which suggest to us that somehow the SHP2/RAS/MAP kinase pathway mediates production of an inhibitor of osteoclast formation, which we are not going to address further here. These mice also had increased bone formation, that is osteoclast surface, mineral apposition rate and so on. So 00:30:37.0 it is an increased turnover with a net loss of bone. Now, we were interested in how this could be. We're using mice, which of the two individual pathways selectively activated, but we had the opportunity to cross these mice with the IL 6 knock out mice, which we felt might help us further in working this out. And when that was done, we had quite an interesting finding in which what is shown here again is 00:31:09.0 the FF mice with decreased amount of bone, decreased trabecular number, increased osteoclasts and the increased osteoblast. Now, when they were crossed with IL 6 knock out mice. The IL 6 knock out mice, if you recall, has no particular skeletal phenotype in the understood state, but when these were crossed and IL-6 was knocked out as well, these compound mice, there was even less amount of the 00:31:40.0 trabecular bone mass and trabecular number was really further significantly lowered and trabecular separation. The bone formation response was now lost but the resorption response retained. In other words, the increased resorption that we had seen in the original SHP2/RAS/MAP Kinase mice the increased resorption response was retained, but now in the compound mass with IL-6 was deleted as well, 00:32:17.0 the resorption response was retained, but we had lost the formation response that we could except to follow that. So, that indicated to us that this formation response, which we might equate with coupling, let's say, it is an IL-6-dependent process, but of course not necessarily IL-6 itself and that it is most likely derived from the osteoclast. It is interesting that there have been a few papers 00:32:43.0 where this sort of possibility is being raised at this meeting and a particularly interesting one from Dr. Zhao and from Kawaichi Matsuo's group the other day looking for an osteoclast arrived coupling mechanism and the identification of Ephrin B2 and EPH B4 as possible candidates is intriguing, to say the least. Now I am going to move to quite a different line of evidence now to try and invoke the osteoclast. This is 00:33:19.0 evidenced from mouse and human genetics with what I'll call nonresorbing osteoclast and in this, I am going to use work that of Morton Karsdal and his colleagues from Nordic Bioscience and I appreciate the chance to discuss this with Morton and his colleagues and collaborating with them as we are doing now. This slide just illustrates the contribution to resorption that is made by the chloride channel, which 00:33:53.0 provides the chloride ions that are necessary in the suffocation process with ATPAs to provide the hydride ions so that both of these are necessary for the action of enzymes that require acidification, but the other released activity, of course, is protease particularly cathepsin K. And so, what I am going to do is spend a few moments on the clues that we can get from looking at the system. Now chloride-7 00:34:26.0 channel deficiency leads to osteopetrosis and it is summarized on this slide, the human data within tremendous increase in bone. These chloride-7 channel deficient osteoclasts are unable to resolve bone. If we look at the clinical data in summary, this syndrome of autosomal dominant osteopetrosis type 2 ADO2. They do not resorb bone, but they have strikingly high osteoclast numbers, 00:35:00.0 high levels in the circulation of osteoclast markers, low resorption, of course. But they can't resorb, but they look like handsome looking osteoclasts. The interesting thing is that bone formation is normal despite this great increase, decrease in resorption. For example, this reference one is to Dr. Boller's lab and colleagues and they did dynamic histomorphometry to show that so that is the striking thing 00:35:27.0 about this osteopetrotic syndrome. It is similar in infantile malignant osteopetrosis, which is the alfa VB3 the vacuolate ATPAs in activation, which also has high osteoclasts numbers low resorption and normal bone formation pyknodysostosis cathepsin K deficiency, but probably normal osteoclast numbers and low resorption and there has been no dynamic histomorphometry done that I am aware of and 00:35:59.0 osteoporotic patients and the only static histomorphometry is inconclusive. So at the moment we cannot be sure whether bone formation is low or not in these subjects, but I'll just refer to this again in a moment. Now, Morton Karsdal and colleagues have very interesting data with inhibition of acidification with the first of the prototype of drug that is a chloride channel inhibitor. This is 00:36:30.0 looking at human osteoclast on bone and trap staining you can hardly see at this magnification. This is on plastic and this is the pit staining after resorption showing ample resorption of these controlled osteoclasts. Treatment with these chloride channel inhibitor, this is an abstract SU 427 here showed, in fact, that there is actually an increase in the numbers of osteoclast, which looked 00:36:59.0 very healthy, but only in those growing on bone, no difference on the plastic, but these osteoclasts did not resolve any pits. This is looked at quantitatively here again in this abstract and that type of which is in impress showing increase in the amount of this chloride channel inhibitor decreases resorption, but significantly increases the numbers of osteoclasts that are unable to resorb. On the 00:37:27.0 other hand, cathepsin K inhibitor inhibits resorption without any increase in the osteoclast numbers, but the same effect of the chloride channel inhibitor, they found to be obtained with bacillomycin, which is inhibitor of acidification through the vacuole ATPA. So the concept then is of the development of osteoclast that may well be unable to resorb, and in fact, certainly are unable to resorb, 00:37:54.0 but they nevertheless look healthy and maybe they can do other things and maybe amongst those other things as production of factors, which could help to maintain a bone formation in these human subjects. And if one can do it in the mice. And just finally again just recapitulating with regard to cathepsin K, although I said we can be uncertain about what happened to the cathepsin K deficiency in man and Don 00:38:26.0 Kimmell and B. Pennypacker had presented the other day a cathepsin K mouse, in which histomorphometry is being done, in which there was no inhibition of bone formation. So I think that the situation of cathepsin K looks promising in the mouse and then we need to sort out the human situation. Now the next line of evidence is in considering the anabolic action of parathyroid hormone because it seems 00:38:57.0 likely the parathyroid hormone acts on remodeling and that we now have clues that we can get from its action that help us in thinking about this question of osteoclast involvement. More than 10 years ago it was shown in the sheep by Delmas and colleagues that a bisphosphonate given together with PTH in an anabolic mode blocked the anabolic action of PTH. This is the bisphosphate tiludronate 00:39:26.0 showing the PTH anabolic affecting bone formation rate and activation frequency and completely blocked by treating with tiludronate. We know now from the work of Dennis Black and published last year and expanded further this week that in human study that the anabolic effect of PTH (this is in looking at QCT). The anabolic effect of PTH is attenuated by concomitant treatment with alendronate and similar data 00:39:57.0 produced by Finkelstein and colleagues and published in the same issue of the New England Journal of Medicine. So, suggested to us again together with the Delmas data that there is at least some component of resorption that is necessary for the full expression of parathyroid hormones anabolic action. Now, what could that be? Well, I am just going to go to some work that I was able to part of with my 00:40:27.0 colleagues at Lilly, Linda Ma, and Jude Anya in the labs a couple of years ago in which we published in 2001, that if you obviously give continuous PTHrP or PTH, I should say, as was done in this experiment to rats, this was a 6 hour infusion, you get osteoclast formed and resorbing, and you get a tremendous and progressive increase in RANKL production from quite early after starting an infusion and a 00:40:56.0 decrease in OPG. This actually shows the interesting depletion of OPG in the matrix. So, that is with continuous infusion. If you give a single injection, as we did in these experiments, it was quite an interesting response that a single injection of PTH gives a very rapid induction of messenger RNA for RANKL, which is a transient induction and a rapid decrease of messenger RNA for OPG, which is 00:41:22.0 also transient and back to normal to control by 2 or 3 hours and only in this model of the single injection in the rat do any genes that are related to formation get expressed and increased amounts some hours later. We published that and wrote in the paper that well maybe what this meant was that a little bit of resorb, I think we used the words that maybe this was necessary to prepare the bone 00:41:52.0 surface for formation and we got away with that. We said it in the paper. I do not know that I would have let anyone get away with that, but that is what we said, but it remained a very interesting finding that was quite reproducible. So, I think going back in the literature, there is some actually very interesting data and this is from the late 1970s. This is from Mirake Holtrop ME, who many of you 00:42:18.0 will remember, who was associated for some years with Larry Raisz and Mirake was a very, very good electron microscopist of bone and what she did in these experiments was to show using quantitative measures of osteoclast activation, in which she measured the area ruffled border area and the clear zone area of osteoclast on electron microscopy at timed intervals after PTH injection both in 00:42:44.0 rabbits and in TPTX rats and it was quite striking that there was obviously a very rapid activation of osteoclast. This is beginning at 30 minutes here and this slide I think is from the rabbit beginning at 30 minutes and this is a transient activation which lasts up to 3 or 4 hours depending on the dose that is given and only when much larger doses are given would more osteoclasts appear, but at 00:43:09.0 least 12 hours later. So, this is all evidenced that PTH clearly has the capacity rapidly to activate what I presume the existing osteoclast and this is just more of her data with ruffled border as a percentage of the cell as a measure of activation showing this clear effect of PTH at 30 minutes and up to 3 hours, put down again by 6 hours. So, our concept then is that maybe what is happening is 00:43:39.0 that PTH certainly acts on cells of the osteoblast lineage and Russell Turner data that PTH does not affect proliferation, but enhances the differentiation of committed precursors. There is no argument with that and it may well be also that there is a contribution from inhibition of a petrosis. But maybe what is also necessary is the transient and I stress transient activation of 00:44:08.0 osteoclasts that can be achieved by a transient change in RANKL to let that transiently activated osteoclast generate something, which contributes further to this anabolic effect. Now, there is this data that is broadly consistent with this, this is two references to actually Dr. Laurie K. McCauley's group, one they published a few years ago that the PTH anabolic action is lost in the c-fos knockout 00:44:37.0 mouse, which of course cannot generate osteoclast. But most interestingly, a couple of days ago in abstract that Dr. Koh presented from the same group, by transplanting vertebrae from the small c-fos knockout mouse into nude mice and treating with PTH that an anabolic effect on those c-fos knockout vertebrae could be restored implying that they are able to do so because they were able to generate 00:45:04.0 osteoclasts from the host's nude mice. Now, the final bit of evidence is from yet another area and this was really quite a surprise. This is the calcitonin receptor, the genetics of knocking out calcitonin and the calcitonin receptor. Now, the calcitonin was knocked out by the and this is the paper by Bob Gagel's group in the JCI 2 years ago and it was a 00:45:30.0 knockout that also knocked out CGRP, but the extraordinary thing about that was it's a surprise to everyone was that it gave an increased bone mass phenotype, increased trabecular bone, trabecular number and so on, and decreased trabecular separation. Implying that may be calcitonin was an inhibitor of bone formation, which was a bit difficult to work out, but what was entirely consistent with it 00:46:01.0 is the data from the calcitonin receptor heterozygote. This is the work that was published in the general cell biology earlier this year by the groups of Gerard Karsenty at Baylor and Jeff (inaudible) in Melbourne. Using the mice of Debra Galson the calcitonin receptor homozygote is embryo-lethal, but the heterozygote has exactly the same bone phenotype as the calcitonin knockout, thereby really validating the 00:46:28.0 calcitonin knockout data and consistent still with this idea that calcitonin somehow or another is an inhibitor of bone formation. Now, what do we know about calcitonin? Well, I have thought about calcitonin for at least 35 to 38 years and I think the only thing we know that calcitonin does very well is rapidly to inhibit osteoclast activity through in vitro, for example, as Tim Chambers has shown 00:46:56.0 stop its motility, cause its rapid contraction and in vivo we know from ample evidence that it is a rapid inactivating process. So, if we try and put this together with the calcitonin knockout data, a possibility is that calcitonin or something acting through the calcitonin receptor has a function to regulate the active state of the osteoclast and that is necessary to limit the amount of any factor 00:47:26.0 or factors that is produced from the active osteoclast and you remove the capacity of agents through the calcitonin receptor to inhibit that and you get more of its production and increased bone formation. That is probably the greatest fantasy of all these lines of evidence that I have given to you, but I think it is something that again is testable and I think that we can add it to all the others and 00:47:50.0 it contributes to a body of suggestive evidence. So, to summarize that an anabolic stimulus, which might be PTH or whatever does the PTH thing locally, whatever your favorite local generator is PTHrP or the beta-adrenergic system, whatever, acts on the osteoblast lineage, to enhance the differentiation of committed precursors, but it also needs to be able to acutely activate osteoclast. Nothing to 00:48:23.0 do with the prolonged effects that would result in increased numbers and in increased markers and that activation would generate coupling activity, which would be added to the direct effect and necessary for the full expression of the anabolic effect. Now, that is coupling but we need, obviously, to resolve many of those issues. There are, of course, many situations where coupling just pulls apart to 00:48:52.0 some extent. Estrogen withdrawal, aging, osteogenesis imperfecta, weightlessness, and cancer, whether it be the humeral hypercalcemia or myeloma and in growth. Just to take growth and aging for example, this is a slide that Ego Seeman gave me from the data of Michael Parfitt. Lips in the aging individual, representing the increase in mineral thickness in the growing 00:49:20.0 during growth and the decrease during aging, so that our concepts that we often teach or ignorant people like me teach is the coupling. In coupling, you need to replace exactly the amount of burn that has been lost, really is not the case, that it must be that in growth you put back slightly more than you resorbed and in advancing age you put back somewhat less that has been resorbed and there may be 00:49:50.0 some part in the middle of life, which Ego colorfully says could be half-an-hour or 3 weeks where the two are absolutely the same. These are the questions that we have to sort out and if the osteoclast makes a factor or factors, which contribute quantitatively to the amount of coupling, and I would suggest that that is possible, then understanding what that is would help us I think in understanding these 00:50:20.0 mechanisms. So, what would be the implications of such a factor or factors? Well, it could represent a new anabolic pathway, and particularly if we're right about the calcitonin receptor that maybe by itself. It would promote bone formation or at least help. It would help us in thinking about antiresorptives that do not inhibit bone formation. If you've got no osteoclasts around at all, then you would not be 00:50:45.0 able to generate activity to contribute to this process, but there are ways of going to antirecsorptives that what would be required is an antiresorptive that did not completely remove the capacity of some appropriate cells to be activated and there is evidence already, that this is the case with estrogen and maybe SERMS and certainly with the acidification inhibitors and maybe the cathepsin K 00:51:11.0 inhibitors. So, for similar reasons, it's got implications for combining anabolics with antireceptors and, of course, in the pathogenesis of disease whether it would be osteoarthrosis, osteopetrosis, cancer, or Paget's disease. So, in summary, I have briefly summarized how the cells of the osteoblast lineage communicate with the hemopoietic lineage and amongst each other to generate the formation 00:51:39.0 and activity of osteoclast. I have mentioned a little about the cells of the immune system and how they are involved both in the production of activators and of inhibitors and they produce so many inhibitors that inhibition must be important from the evolutionary point of view, which is something we need to think about. I have mentioned the resorption of matrix growth factors and I 00:52:03.0 put in a dotted line, simply because I do not like it, but I might be totally wrong about that and I certainly would not want to exclude it, but I think maybe more what I favor more is the fact that the osteoblasts themselves communicate to decide how much work they need to do to fill up that space and that also is a testable hypothesis. And finally, the intriguing possibility that the osteoclast 00:52:29.0 themselves produce a factorial factors, which act on the osteoblast lineage in the coupling process to determine how much formation takes place. Finally, I want to thank a number of people and my colleagues at the institute, particularly Natalie, Julian Quinn, Kong Wah Ng, and Matthew Gillespie. My long and happy association working with Jude Onyia and Linda Ma and the colleagues at the 00:52:58.0 Lilly Labs, particularly thank Morten Karsdal amd Kim Hinrichsen for the insights that we get from the work that during my long and very productive and happy association with the group that was at Showa, now at Matsumoto University, Nobi Udagawa, and Nao Takahashi, with Tatsuo Suda when he was at Showa with Matthias Ernst and Brendan Jenkins in the Ludwig Institute in Melbourne for the mice that 00:53:24.0 they are happy to have us work with. I had many very fruitful discussions with Ego Seeman over the last months about this topic and I am most grateful to Ego for his insights and criticisms. To Alan Boyde, who is such a wonderful contributor and who has been very helpful, and to Gideon for all the insights very early in the 25 years ago, but also in the last few weeks he has put me straight on a number of these issues when I sent him material, so I thank you very much. 00:54:03.0 There is time for some questions, if people want to come to the microphones. --It would be much better if there were no questions, Larry. We are not surprised. That was wonderfully thought provoking and then I got stuck in something and I am not sure how important it is and that is the reversal 00:54:29.0 phase. If it is true that there is a reversal phase in bone remodeling and there are mononuclear cells sitting there for days or possibly even weeks, does that separate the osteoclast and the osteoblast are those cells part of the osteoclast system. 00:54:44.0 Well, that may well be, if they are macrophages that are doing it, but, of course there is no evidence from Dr. Evertson and colleagues that learning cells might be doing this by production of proteases. I think the timing is difficult. There is no question about that and so that may well be that early on there is a signal required to dictate how many precursors (inaudible) that can be available and that may not be one that is delayed, but we do not know. That will have to be tested. 00:55:29.0 Just to follow up on that, is the reversal phase really identified in our rodent models? --I have never seen a clear identification of a rodent reversal phase. --(inaudible) data is in rodents. --It is. --Yes. --Microphone #1, Lance Lanyon, London. 00:55:47.0 Presumably, Jack, the purpose of coupling to restore the amount of bone that you took away is essentially a structural one, and I am interested that you did not refer to the possibility that actually the fine tuning of the coupling to ensure complete restitution where function is continuing, but allow bone loss in a situation, for instance, of weightlessness might be contributed by the resident bone cells having a strain related mechanism. --Yeah. 00:56:16.0 That overcomes the problem of timing that Larry has just referred to because, the inappropriate strain signal is going to continue until you've got the amount of restitution necessary to get rid of it. --Sure, you are absolutely right, Lance. I thought about how I could include osteocytes in this consideration and I think we have to do that, but I thought it was getting complicated enough without doing that, but you are absolutely right, I could not agree more. 00:56:43.0 Microphone 4, Rajka from Merck. --Jack, I am wondering if you think there could be perhaps more than one flavor of bone formation and I am thinking about more of the periosteal bone formation where we do not have much --I cannot hear you very well. 00:56:56.0 Sorry. At the periosteum there is not very much bone resorption going on and clearly PTH favors the endocortical surface especially at lower doses, but other ligands, for instance from VDR, can very nicely stimulate bone formation in animal models at the periosteum and I wonder if you think that there could be perhaps resorption independent effects. 00:57:20.0 Oh, yeah absolutely. This by no means excludes that possibility, and in fact, we talk about this coupling activity as enhancing the anabolic response and being necessary for its full expression, but it does not alter the fact that and maybe if you give enough PTH in the presence of a good going resorption inhibitor, you could get a reasonable response. 00:57:52.0 In theory, that could be more of an avenue where you might have a better coupling between antiresorptive as a combination therapy with an anabolic, if they were acting on different surfaces putatively, you would not have a negative impact. ---Stavros, there is time for one quick question. --Yea, Michael Parfitt is telling me it is very difficult to teach old dogs new tricks. The new tricks here are the wind signaling and the BMP, what do you think of their role in the coupling.
